Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study

Katsuhiro Oda1, Takuya Kotani2, Tohru Takeuchi1

  • 1Department of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka, Japan.

Scientific Reports
|May 11, 2017
PubMed

Insights

Serum C-C motif chemokine ligand 2 (CCL2) levels predict prognosis in dermatomyositis with interstitial pneumonia (DM-IP). Higher initial CCL2 levels indicate a poorer prognosis, and CCL2 may guide initial treatment decisions for DM-IP patients.

Area of Science:

  • Immunology
  • Pulmonology
  • Rheumatology

Background:

  • Chemokines are implicated in the pathology of dermatomyositis with interstitial pneumonia (DM-IP).
  • The prognostic significance of chemokine profiles in DM-IP remains unclear.

Purpose of the Study:

  • To investigate the relationship between serum chemokine levels and disease activity or prognosis in DM-IP.
  • To identify potential chemokine biomarkers for predicting outcomes in DM-IP.

Main Methods:

  • Serum levels of CCL2, CXCL9, CXCL10, CXCL11, and CCL17 were measured in 30 DM-IP patients.
  • Correlation analysis was performed between chemokine levels, disease activity, and prognosis.
  • Receiver operating characteristic (ROC) curve analysis determined prognostic cut-off points for CCL2.

Main Results:

  • Initial serum CCL2 levels were significantly higher in patients who died (P=0.007).
  • A CCL2 level of 894 pg/mL was identified as a poor prognostic factor (sensitivity: 100%, specificity: 70.8%).
  • Chemokine levels (CCL2, CXCL10, CXCL11) at 2 weeks post-treatment were higher in the non-survivor group.

Conclusions:

  • Serum CCL2, CXCL10, and CXCL11 levels may serve as biomarkers for disease activity and prognosis in DM-IP.
  • Initial serum CCL2 levels could aid in guiding treatment decisions for DM-IP.

Related Concept Videos